Cross-industry discussion is expanding from early discovery to post-licensing challenges – as the nexus of innovation and policy improvements is rapidly changing, says DIA executive.
There is an increased need for transparency to improve the conduct of pediatric clinical trials and enhance the site investigator experience, says Syneos executive.
The drug development “finish line” is not regulatory approval, says Syenos Health chief scientific officer Judith Ng-Cashin, MD, who discusses bringing the payer and patient voice into the process.
PPD Laboratories SVP says its been a substantial undertaking – for every company in the CRO industry – to meet the demand for biopharmaceuticals as the industry's pipeline continues to expand.
Advanced imaging in drug discovery aims to improve the success rate of drug development as the industry continues to tackle devastating diseases such as Alzheimer’s – but no research lab can do it alone, says Charles River managing director.
When translational medicine researchers recognise the need for pharma industry cash but are wary of handing over drug development to for-profit organisations, how can public-private collaborations bridge the culture gap?
The holidays are fast upon us, so let’s put ‘business’ to one side and get into the festive mood. To keep in the spirit of things, we’ve got a ‘gift’ for you – enjoy. Happy Holidays!
Aenova says the acquisition of Haupt Pharma and Patheon’s merger with DSM are evidence of consolidation in the CMO industry, as it looks to further increase its global footprint.
Catalent has increased its stake in Redwood Biosciences telling us it is committed to the development of antibody-drug conjugates (ADCs) and the SMARTag technology platform.
Patheon and DSM’s Pharma Products merger is “highly complementary” with crossover limited to North American oral solid manufacturing growth, says DPx as it targets further growth opportunities.
Biopharma companies are looking for more pre-fabrication of their facilities and to be able to expedite construction and meet tighter timelines, an expert told Outsourcing-Pharma.com.
Following the completion of remediation efforts to deal with an FDA warning letter, Chris Phillips, AMRI's senior director of its Burlington, Massachusetts site, discusses what he considers to be a "new bar" in enforcement activity from...
